DNA (DNA)

Financial Metrics & Valuation Analysis

Enterprise Valuation (TTM)

Enterprise Value$795.31M
EV / Sales5.63
EV / EBITDA-3.77
EV / Operating Cash Flow-4.79
EV / Free Cash Flow-4.34

Return Metrics (TTM)

Return on Equity (ROE)-57.31%
Return on Assets (ROA)-29.46%
Return on Invested Capital (ROIC)-31.12%
Return on Capital Employed (ROCE)-31.22%

Yield Metrics

Earnings Yield-63.17%
Free Cash Flow Yield-34.68%

Balance Sheet Strength

Net Debt / EBITDA-1.27
Current Ratio5.15
Working Capital$330.36M
Tangible Asset Value$394.29M
Net Current Asset Value-$179.97M

Working Capital Efficiency

Days Sales Outstanding51.18
Days Payables Outstanding168.30
Operating Cycle (Days)51.18
Cash Conversion Cycle-117.11

Capital Allocation

CapEx / Revenue12.24%
CapEx / Operating Cash Flow-10.42%
R&D / Revenue157.65%
SG&A / Revenue121.77%

Fiscal Year 2025 Ratios

Audited annual results as of 2025-12-31

Margins

Gross Profit Margin81.48%
Operating Margin-185.29%
Net Profit Margin-183.81%

Solvency

Debt / Equity0.86
Quick Ratio4.92
Cash Ratio1.74

Per Share

Revenue / Share$3.07
FCF / Share-$3.22
PE Ratio-1.47